Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today ...
Quoin Pharmaceuticals (QNRX) announces interim clinical data from its ongoing Investigator Pediatric Netherton Syndrome clinical study. The ...
Continued Significant Improvement in Skin Appearance Observed in StudySubject’s Disease Classification Improved from “Severe” ...
In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report), with a ...
Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label Study ...
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical ...
Denise Carter, the Chief Operating Officer of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX), recently made significant purchases of the company's stock. According to a filing with the Securities and ...
Senores Pharmaceuticals IPO Allotment Today: At the upper price band, the company is valued at a P/E of 55x with a market cap of Rs 1800.6 crore (Image: Freepik) Senores Pharmaceuticals IPO closes ...
ASHBURN, Va. - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical stage pharmaceutical company with a current market capitalization of $3.27 million and a healthy current ratio of 3.02, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback